Longitudinal analyses of healthcare resource utilization and costs among patients with obstructive hypertrophic cardiomyopathy
Open Access
- 16 November 2025
- journal article
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 28 (1) , 1979-1988
Abstract
Obstructive hypertrophic cardiomyopathy (oHCM) is associated with substantial disease burden, healthcare resource utilization (HCRU), and healthcare costs. This study assessed HCRU and healthcare costs among patients with oHCM treated in real-world settings over 5 years of follow-up. This retrospective cohort study used the Optum database (January 2013-December 2021) and included patients aged ≥18 years with ≥2 claims for oHCM and continuous health plan enrollment for ≥6 months pre-initial and post-initial oHCM claim (index date). Patients with ≥5 years of follow-up data were analyzed. All-cause and HCM-related HCRU (ambulatory visits [physician office visits and outpatient visits], emergency room [ER] visits, hospital admissions, length of stay [LOS], and pharmacy use) and healthcare costs were assessed in US dollars. In total, 5,129 patients with oHCM were identified: 5,056 (98.6%) had an all-cause ambulatory visit and 4,669 (91.0%) had an HCM-related visit. 4,079 (79.5%) had an all-cause ER visit, and 1,499 (29.2%) an HCM-related ER visit. 2,949 (57.5%) reported an all-cause admission, and 2,232 (43.5%) an HCM-related admission. The mean (SD) per-person count of all-cause ambulatory visits was 101.0 (90.7) and 15.3 (18.7) for HCM-related ambulatory visits. Mean (SD) all-cause admissions per patient were 1.8 (3.8), and 0.9 (1.6) were HCM related. Mean (SD) all-cause LOS was 18.0 (54.7) days, and HCM-related LOS was 10.0 (39.6) days. Mean (SD) all-cause healthcare cost per patient was $181,968 (241,608), of which $67,531 (114,705) was HCM related. Hospital admissions were the largest proportion of medical costs: all-cause admissions cost $71,001 (149,533) during follow-up, of which $44,781 (99,431) was HCM-related. Analyses were unadjusted for covariates or confounding factors. Patients with oHCM experience substantial HCRU and costs over 5 years of follow-up. These results indicate a need for new treatment options which could decrease HCRU and improve patient outcomes.Keywords
Funding Information
- Cytokinetics
This publication has 16 references indexed in Scilit:
- Clinical Outcomes, Resource Utilization, and Treatment Over the Disease Course of Symptomatic Obstructive Hypertrophic Cardiomyopathy in the United StatesThe American Journal of Cardiology, 2023
- Electronic health record data for assessing risk of hospitalization for COVID-19: Methodological considerations applied to multiple sclerosisMultiple Sclerosis and Related Disorders, 2023
- Contemporary Therapies and Future Directions in the Management of Hypertrophic CardiomyopathyCardiology and Therapy, 2022
- Expenditure on Heart Failure in the United StatesJACC: Heart Failure, 2022
- Characteristics of Patients With Obstructive Hypertrophic Cardiomyopathy in Real-World Community-Based Cardiovascular PracticesThe American Journal of Cardiology, 2022
- Treatment Changes, Healthcare Resource Utilization, and Costs Among Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Claims Database StudyCardiology and Therapy, 2022
- Healthcare resource utilization and cost of obstructive hypertrophic cardiomyopathy in a US populationAmerican Heart Journal Plus: Cardiology Research and Practice, 2022
- Clinical Diagnosis of Hypertrophic Cardiomyopathy Over Time in the United States (A Population-Based Claims Analysis)The American Journal of Cardiology, 2021
- Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United StatesJournal of Medical Economics, 2021
- Occurrence of Clinically Diagnosed Hypertrophic Cardiomyopathy in the United StatesThe American Journal of Cardiology, 2016